RPID shareholders will receive just $0.75 per share in an all-cash transaction; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers
CLICK HERE TO JOIN
MILWAUKEE, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating whether the proposed acquisition of Rapid Micro Biosystems (NASDAQ: RPID) by Merck, provides fair value to Rapid Micro Biosystems’ public shareholders and whether Rapid Micro Biosystems’ Board adequately protected shareholder interests in negotiating and approving the transaction.
Are You a RPID Shareholder?
If you own Rapid Micro Biosystems shares, Ademi LLP would like to hear from you about the proposed acquisition and your rights as a shareholder.
You may also contact Guri Ademi at gademi@ademilaw.com or toll-free at 866-264-3995.
There is no cost or obligation to you.
What Is Ademi LLP Investigating?
- The purchase price and whether it adequately reflects Rapid Micro Biosystems’ value and future prospects;
- Substantial change-of-control benefits available to Rapid Micro Biosystems insiders in connection with the transaction;
- Restrictions on competing transactions, including a significant termination penalty that may discourage another potential buyer from making a superior proposal; and
The conduct of Rapid Micro Biosystems’ Board of Directors in negotiating and approving the transaction and whether the Board fulfilled its duties to public shareholders.
What Should RPID Shareholders Do?
Contact Ademi LLP to discuss your rights and our investigation. There is no cost or obligation to you.
Guri Ademi
Ademi LLP
Toll Free: (866) 264-3995
Email: gademi@ademilaw.com
About Ademi LLP
Ademi LLP represents investors in shareholder litigation involving mergers, acquisitions, buyouts, and individual shareholder rights.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Ademi LLP

